证券代码：688265 证券简称：南模生物 公告编号：2025-069 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 上海南方模式生物科技股份有限公司（以下简称"公司"）邮箱 ir@modelorg.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 公司已于 2025 年 10 月 30 日发布公司《2025 年第三季度报告》， 为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 财务状况，公司计划于 2025 年 11 月 13 日（星期四）15:00-16:30 参 加 2025 年上海辖区上市公司三季报集体业绩说明会，就投资者关心 的问题进行交流。 会议召开时间：2025 年 11 月 13 日（星期四）15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow. ...

Core Points - Nanmo Biology's stock price fell by 3.72% to 48.72 yuan on November 3 [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an initial offering price of 84.62 yuan per share [1] - The stock is currently in a state of decline, having reached a peak price of 82.00 yuan on its first trading day [1] Fundraising and Financials - Nanmo Biology raised a total of 1.649 billion yuan through its initial public offering (IPO), with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan [1] - The company planned to use the funds for various projects, including a biological research base, a genetically modified model resource library, and working capital [1] Issuance Costs - The total issuance costs for the IPO amounted to 181 million yuan, with underwriting fees accounting for 158 million yuan [1]

Core Insights - The medical services sector experienced a rise of 1.67% on October 31, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 34.46, up 11.20% with a trading volume of 158,200 shares and a transaction value of 530 million [1] - Other notable performers included: - Nanmo Biological (688265) at 50.60, up 9.98% [1] - Nuo Si Ge (301333) at 68.59, up 7.00% [1] - Yangguang Nuohe (688621) at 58.75, up 5.10% [1] - *ST Biological (000504) at 9.57, up 5.05% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 461 million from institutional investors, while retail investors experienced a net inflow of 918,230 [2] - Notable capital flows included: - Innovation Medical (002173) with a net inflow of 14.416 million from institutional investors [3] - Tai Ge Medical (300347) with a net inflow of 70.6534 million from institutional investors [3] - Zhaoyan New Drug (603127) with a net inflow of 53.6731 million from institutional investors [3]

Group 1 - The core viewpoint of the news is that Nanmo Biological has seen a stock price increase of 5.09%, reaching 48.35 yuan per share, with a total market capitalization of 3.77 billion yuan [1] - Nanmo Biological, established on September 20, 2000, specializes in the research, production, and sales of genetically modified animal models, with its main business revenue composition being: standardized models 48.34%, model technical services 21.92%, model breeding 19.50%, customized models 9.34%, and others 0.91% [1] Group 2 - Tianhong Fund's Tianhong Medical Health A (001558) has entered the top ten circulating shareholders of Nanmo Biological, holding 377,400 shares, which is 0.48% of the circulating shares, with an estimated floating profit of approximately 883,200 yuan [2] - Tianhong Medical Health A was established on June 30, 2015, with a latest scale of 263 million yuan, and has achieved a year-to-date return of 36.83% [2] Group 3 - The fund manager of Tianhong Medical Health A is Lü Qiao, who has a total fund asset scale of 506 million yuan, with the best fund return during the tenure being 41.15% and the worst being 40.68% [3]

Core Viewpoint - Nanmo Bio is a leading supplier of genetically modified animal models in China, providing critical technical support for the biopharmaceutical industry with a full industry chain service capability [1] Group 1: Business Performance - In Q3 2025, Nanmo Bio achieved a revenue of 303 million yuan, ranking 24th among 29 companies in the industry [2] - The company's net profit for the same period was 26.76 million yuan, placing it 19th in the industry [2] - Revenue breakdown: standardized models accounted for 48.34% (94.62 million yuan), model technical services for 21.92% (42.90 million yuan), model breeding for 19.50% (38.17 million yuan), customized models for 9.34% (18.29 million yuan), and other revenue for 0.91% (1.77 million yuan) [2] Group 2: Financial Ratios - As of Q3 2025, Nanmo Bio's debt-to-asset ratio was 10.38%, down from 11.82% year-on-year and significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The company's gross profit margin was 52.87%, an increase from 43.63% year-on-year and above the industry average of 37.70%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 2.53% to 6,687, while the average number of circulating A-shares held per shareholder decreased by 2.47% to 11,700 [5] - Tianhong Medical Health A became a new major shareholder with 377,400 shares, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [5] Group 4: Executive Compensation - The chairman, Fei Jian, received a salary of 500,000 yuan in 2024, an increase of 100,000 yuan from 2023 [4] - The company is controlled by Shanghai Dish Enterprises Management Consulting Co., Ltd., with Wang Mingjun and Fei Jian as the actual controllers [4]

Core Insights - Nanmo Biological (688265.SH) reported a total operating revenue of 303 million yuan for Q3 2025, ranking 35th among disclosed peers [1] - The company's net profit attributable to shareholders was 26.76 million yuan, ranking 25th among disclosed peers [1] - Operating cash flow was 19.64 million yuan, ranking 29th among disclosed peers [1] Financial Metrics - The latest debt-to-asset ratio is 10.38% [3] - The latest gross profit margin is 52.87% [3] - The latest return on equity (ROE) is 1.57%, ranking 25th among disclosed peers [3] - The diluted earnings per share (EPS) is 0.34 yuan [3] - The total asset turnover ratio is 0.16 times, ranking 35th among disclosed peers [3] - The inventory turnover ratio is 9.37 times [3] Shareholder Information - The number of shareholders is 6,687, with the top ten shareholders holding 58.58 million shares, accounting for 75.13% of the total share capital [3] - The top ten shareholders and their holdings are as follows: - Shanghai Dish Stone Enterprise Management Consulting Co., Ltd.: 35.6% - Shanghai Science and Technology Venture Capital Co., Ltd.: 13.81% - Suzhou Haiwang Hezhong No.1 Equity Investment Partnership (Limited Partnership): 11.1% - Shanghai Pudong New Industry Investment Co., Ltd.: 7.86% - Kangjun Investment Management (Beijing) Co., Ltd.: 2.00% - Zhang Kui: 2.00% - Qu Fabing: 1.01% - Shanghai Huashen Asset Management Co., Ltd.: 0.64% - Shanghai Puyu Enterprise Management Consulting Partnership (Limited Partnership): 0.58% - China Merchants Securities Co., Ltd.: 0.48% [3]

Core Insights - The company Nanmo Biology (688265.SH) reported a total revenue of 303 million yuan for the first three quarters of 2025, representing a year-on-year growth of 14.29% [1] - The net profit attributable to shareholders was 26.76 million yuan, a significant improvement from a loss of 15.19 million yuan in the same period last year [1] - The basic earnings per share stood at 0.34 yuan [1]

Group 1 - Company Nanmo Bio reported a revenue of approximately 303 million yuan for the first three quarters of 2025, representing a year-on-year increase of 14.29% [1] - The net profit attributable to shareholders of the listed company was approximately 26.76 million yuan, with a basic earnings per share of 0.34 yuan [1] - As of the report date, the market capitalization of Nanmo Bio was 3.6 billion yuan [2] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [2] - A new "slow bull" market pattern is emerging, indicating a shift in market dynamics [2]

Financial Performance - The company's operating revenue for the third quarter reached ¥106,937,671.62, representing a year-on-year increase of 21.52%[3] - The total profit for the third quarter was ¥8,149,982.96, with a net profit attributable to shareholders of ¥8,597,530.11[3] - Year-to-date revenue as of the reporting period was ¥302,700,815.36, showing a 14.29% increase compared to the same period last year[3] - The company reported a significant increase in net profit attributable to shareholders for the quarter, with a year-on-year growth of 242.07%[9] - Total operating revenue for the first three quarters of 2025 reached ¥302.70 million, an increase of 14.26% compared to ¥264.85 million in the same period of 2024[18] - Operating profit for the first three quarters of 2025 was ¥26.56 million, a significant turnaround from a loss of ¥20.81 million in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥26.76 million, compared to a net loss of ¥15.20 million in the same period of 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.34, recovering from a loss of ¥0.20 per share in the same period of 2024[19] Research and Development - Research and development expenses totaled ¥21,128,375.40 for the quarter, accounting for 19.76% of operating revenue, a decrease of 1.18 percentage points year-on-year[4] - Research and development expenses increased to ¥62.72 million, up from ¥57.23 million, indicating a focus on innovation[18] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥19,641,082.96[3] - The company's cash and cash equivalents as of September 30, 2025, amount to ¥123,995,787.94, down from ¥200,731,445.41 at the end of 2024[14] - Total assets as of the reporting period were ¥1,899,214,539.20, reflecting a decrease of 1.56% from the end of the previous year[4] - Total assets decreased to ¥1,899.21 million from ¥1,929.36 million, a decline of 1.56%[16] - The company's cash flow from operating activities is yet to be detailed in the provided data, indicating potential areas for future reporting[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,687[12] - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, representing 35.62% of total shares[12] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[14] - There are no significant related party transactions or actions among shareholders reported[13] - The company has not received any notifications regarding other shareholders having related party relationships or acting in concert[13] Government and Market Strategy - The company expects to continue strengthening its domestic market presence, contributing to revenue growth and cost control measures[9] - Government subsidies received during the year have increased compared to the previous year, positively impacting the financial results[9] - The company is focusing on market expansion and new product development, as indicated by the increase in R&D expenses[18] Liabilities and Costs - Total liabilities decreased to ¥197.12 million from ¥246.36 million, a reduction of 20%[16] - Total operating costs decreased to ¥285.43 million from ¥296.66 million, reflecting a reduction of 3.93%[18] Cash Flow Activities - Cash inflow from operating activities totaled $283,031,576.85, an increase from $250,814,892.48 in the previous period, reflecting a growth of approximately 12.8%[22] - Net cash flow from operating activities improved to $19,641,082.96, compared to a negative cash flow of $6,582,776.74 in the prior period[22] - Cash inflow from investment activities reached $2,351,249,376.76, significantly higher than $1,663,787,664.49, marking an increase of about 41.3%[22] - Net cash flow from investment activities was negative at -$81,472,532.88, a decline from a positive cash flow of $54,334,669.66 previously[22] - Cash outflow from financing activities amounted to $14,702,993.05, down from $77,741,015.51, indicating a reduction of approximately 81.1%[23] - The net increase in cash and cash equivalents was -$77,207,060.17, compared to -$29,444,646.47 in the previous period[23] - The ending balance of cash and cash equivalents stood at $119,007,785.43, up from $68,158,274.93 at the end of the previous period[23] - The company reported a cash inflow of $2,351,180,132.49 from the recovery of investments, compared to $1,663,733,736.39 previously, reflecting a growth of approximately 41.4%[22] - Payments to employees increased to $143,887,427.60 from $136,133,446.55, representing a rise of about 5.1%[22] Accounting Standards - The company did not execute any new accounting standards or interpretations for the year 2025[24]

证券代码：688265 证券简称：南模生物 公告编号：2025-067 公司网址：https://www.modelorg.com/ 投资者邮箱：ir@modelorg.com 上海南方模式生物科技股份有限公司 关于变更主要办公地址的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"）因内部管理需 要，于近日对主要办公地址进行了调整，为方便投资者与公司沟通和交流，现 将公司主要办公地址和投资者联系方式相关情况公告如下： 一、公司联系方式变更情况 | 主要办公地址 | 上海市浦东新区琥珀路 | | | 63 | 上海市浦东新区琥珀路 63 | | --- | --- | --- | --- | --- | --- | | 联系方式 | | 弄 号 1 6 | 变更前 层 | | 变更后 弄 号 1 | 二、公司最新联系方式 公司除主要办公地址变更外，投资者热线等联系方式未发生变化，具体联 系方式如下： 投资者热线：021-58120591 公司传真：021-2079115 ...